Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Friday the receipt of the US FDA approval for the generic version of BiCNU (carmustine) for injection in 100 mg.
In conjunction, the company plans to launch its Carmustine for Injection in November 2018. Carmustine is a medication used mainly for chemotherapy.
For the 12 months ended August 2018, the US market annual sales for Carmustine for Injection USP in 100 mg/vial is estimated to be about USD84m, according to IQVIA.
Headquartered in Bridgewater, NJ, the specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules